Fitzsimon_menu

Find out what's happening on campus and across the industry.

Read Fitzsimons Innovation Community news, industry highlights, editorials, and innovation updates happening weekly on our campus.

Atara Biotherapeutics
News | Jul 17, 2024

Atara Biotherapeutics

Today Atara announced that the FDA has accepted its Biologics License Application (BLA) and granted Priority Review with a January 15, 2025 hashtag#PDUFA date for tabelecleucel (tab-cel®) as monotherapy for treatment of adult and pediatric patients two years of age and older with Epstein-Barr virus (hashtag#EBV) positive post-transplant lymphoproliferative disease (hashtag#PTLD) who have received at least one prior therapy. For solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate. If approved, tab-cel would be the first approved therapy in the U.S. for EBV+ PTLD. Read the press release for more: https://bit.ly/46bainx

DARTNet enhances and enlarges clinical decision support for clinicians
News | Jul 03, 2024

DARTNet enhances and enlarges clinical decision support for clinicians

DARTNet leaders Wilson Pace and John Westfall co-author "An Exploratory Study of Physician Decision-Making When Treating Uncontrolled COPD" in International Journal of Chronic Obstructive Pulmonary Disease.

Companies selected to present at CBSA’s 2024 Rocky Mountain Life Sciences Investor & Partnering Conference
News | Jul 02, 2024

Companies selected to present at CBSA’s 2024 Rocky Mountain Life Sciences Investor & Partnering Conference

Congratulations to the startup, emerging, and growth companies selected to present at CBSA’s 2024 Rocky Mountain Life Sciences Investor & Partnering Conference, chosen by a panel of experts. Shout out to Fitzsimons Innovation Community Members, EnteroTrack, GelSana, RheumaGen, and Vona Oncology. among those selected.

Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute
News | Jul 01, 2024

Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute

Charles River Laboratories International, Inc. (NYSE: CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral vector contract development and manufacturing organization (CDMO) agreement. Gates Institute will leverage Charles River’s premier cell and gene therapy CDMO expertise to develop Good Manufacturing Practice (GMP)-grade lentiviral vectors (LVVs) for use in novel chimeric antigen receptor (CAR) T-cell therapies for hematological cancers.

Colorado Tech Blog Features GelSana’s Innovative Materials
News | Jul 01, 2024

Colorado Tech Blog Features GelSana’s Innovative Materials

Colorado Tech Spotlight features a profile of GelSana and how this Fitzsimons Innovation Community company is disrupting the field of wound care. Discover how it works, the story behind it, and how the Colorado life sciences and medical technology community comes together to collaborate and grow our state's prominence in the field.